TQB2825

TQB2825 is a bispecific antibody developed by Chia Tai Tianqing Pharmaceutical and Shanghai Chia Tai Tianqing Pharmaceutical Technology Development. Its targets are CD20 and CD3 (the sponsor names CD3 x CD20). ClinicalTrials.gov describes the intervention as: Drug: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection; Other Name: Gemcitabine Hydrochloride for Injection, Zefei; Oxaliplatin for Injection, Aihen TQB2825 injection is Cluster of Differentiation 3 (C. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in diffuse large B-cell lymphoma. The largest, NCT06829771, plans to enrol 90 participants with primary completion expected 2026-05. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.